NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Scancell Holdings plc (LSE: SCLP)

 
SCLP Technical Analysis
3
As on 20th Dec 2024 SCLP STOCK Price closed @ 11.00 and we RECOMMEND Sell for LONG-TERM with Stoploss of 11.20 & Sell for SHORT-TERM with Stoploss of 11.29 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

SCLPSTOCK Price

Open 11.00 Change Price %
High 11.30 1 Day 0.00 0.00
Low 10.70 1 Week -0.50 -4.35
Close 11.00 1 Month -2.75 -20.00
Volume 140287 1 Year 2.25 25.71
52 Week High 19.50 | 52 Week Low 8.15
 
LSE UK Most Active Stocks
TRP 0.04 %
LLOY 54.20 -0.18%
DKE 0.15 0.00%
ORCP 0.02 -33.33%
NNN 0.09 50.00%
DMTR 0.03 0.00%
BOIL 0.08 0.00%
VOD 66.50 -0.84%
MCLS 1.68 46.09%
DIS 0.12 0.00%
 
LSE UK Top Gainers Stocks
0YY7 20.40 280.60%
SSIF 18.50 208.33%
CGW 55.03 107.66%
CNN 65.00 85.71%
VENC 139.60 65.21%
0UTC 0.41 51.85%
NNN 0.09 50.00%
NNN 0.09 50.00%
TIR 0.15 50.00%
MCLS 1.68 46.09%
 
LSE UK Top Losers Stocks
DNA 0.06 -99.90%
DNA 0.06 -99.90%
DNA 0.06 -99.90%
DNA 0.06 -99.90%
JPE 12.55 -98.66%
SPPC 0.15 -93.75%
AGM 1.00 -80.95%
AGM 1.00 -80.95%
AGM 1.00 -80.95%
0L7R 0.29 -78.20%
 
 
SCLP
Daily Charts
SCLP
Intraday Charts
Whats New @
Bazaartrend
SCLP
Free Analysis
 
SCLP Important Levels Intraday
RESISTANCE12.16
RESISTANCE11.79
RESISTANCE11.56
RESISTANCE11.33
SUPPORT10.67
SUPPORT10.44
SUPPORT10.21
SUPPORT9.84
 
SCLP Forecast December 2024
4th UP Forecast31.64
3rd UP Forecast25.02
2nd UP Forecast20.93
1st UP Forecast16.84
1st DOWN Forecast5.16
2nd DOWN Forecast1.07
3rd DOWN Forecast-3.02
4th DOWN Forecast-9.64
 
SCLP Weekly Forecast
4th UP Forecast16.78
3rd UP Forecast14.93
2nd UP Forecast13.78
1st UP Forecast12.64
1st DOWN Forecast9.37
2nd DOWN Forecast8.22
3rd DOWN Forecast7.07
4th DOWN Forecast5.22
 
SCLP Forecast2024
4th UP Forecast34.43
3rd UP Forecast26.92
2nd UP Forecast22.27
1st UP Forecast17.63
1st DOWN Forecast4.37
2nd DOWN Forecast-0.27
3rd DOWN Forecast-4.92
4th DOWN Forecast-12.43
 
 
SCLP Other Details
Segment EQ
Market Capital 163043792.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
SCLP Address
SCLP
 
SCLP Latest News
 
Your Comments and Response on Scancell Holdings plc
 
SCLP Business Profile
Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 that is in phase I/II combination trials for the treatment of non-small cell lung cancer; and Modi-1, which is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2 that is in pre-clinical trial for the treatment of multiple solid tumors. The company has a research collaboration agreement with BioNTech to develop T-cell receptor based therapeutics; licensing and collaboration agreement with ISA Pharmaceuticals B.V. to use ISA's AMPLIVANT adjuvant technology for the development and commercialization of Modi-1; and collaboration agreements with Cobra Biologics, Centre for Research on Global Virus Infections, the University of Nottingham, and the Nottingham Trent University to develop a vaccine for COVID-19. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom. Address: John Eccles House, Oxford, United Kingdom, OX4 4GP
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service